Cardiology journal最新文献_第3页

Association between renal function and arterial stiffness among women with systemic lupus erythematosus or antiphospholipid syndrome. 系统性红斑狼疮或抗磷脂综合征女性的肾功能和动脉僵硬之间的关系。

Cardiology journal Pub Date : 2025-07-09 DOI: 10.5603/cj.102298

Ewa Pędzich, Adrian Bednarek, Dominika Klimczak-Tomaniak, Anna Apanel-Kotarska, Adam Rdzanek, Emilia Włoszek, Ewa Kuca-Warnawin, Marcin Grabowski, Marzena Olesińska, Mariusz Tomaniak

{"title":"Association between renal function and arterial stiffness among women with systemic lupus erythematosus or antiphospholipid syndrome.","authors":"Ewa Pędzich, Adrian Bednarek, Dominika Klimczak-Tomaniak, Anna Apanel-Kotarska, Adam Rdzanek, Emilia Włoszek, Ewa Kuca-Warnawin, Marcin Grabowski, Marzena Olesińska, Mariusz Tomaniak","doi":"10.5603/cj.102298","DOIUrl":"https://doi.org/10.5603/cj.102298","url":null,"abstract":"Background: Patients diagnosed with systemic lupus erythematosus (SLE) or antiphospholipid syndrome (APS) carry a higher risk of atherosclerosis and subsequent major adverse cardiac events; however, the mechanisms of such complications are still not fully understood. Although patients with SLE or APS are also known to have an increased risk of renal function impairment, there are few data on the correlation of augmentation index normalized to 75 beats per minute (AI@75) or pulse wave velocity (PWV) reflecting arterial remodeling, with laboratory tests indicative of renal function in women diagnosed with SLE or APS.Methods: This was a prospective, cross-sectional study that enrolled women with a diagnosis of SLE and/or APS. All patients underwent measurement of carotid-femoral PWV (SphygmoCor XCEL, AtCor Medical Ltd) with pulse wave analysis, calculation of AI@75, and laboratory assessment.Results: A total of 60 women with SLE or APS were enrolled in the study. Urea level was found to correlate with AI@75 (rho = 0.362, p = 0.006) and PWV (rho = 0.487, p = 0.006). In separate adjusted (age, body mass index, and blood pressure) models, urea (B = 0.722, 95% CI: 0.407-1.037, p < 0.001), uric acid (4.932, 95% CI: 0.447-9.418, p = 0.03), creatinine (B for 0.1 mg/dL increase = 3.367, 95% CI: 1.112-5.601, p = 0.004), and eGFR (B = -0.318, 95%CI: -0.580- -0.055, p = 0.02) were associated with AI@75.Conclusions: Urea and uric acid values are associated with increased arterial stiffness measured by non-invasive methods such as PWV and AI@75 in women with SLE or APS with normal or slightly reduced glomerular function.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coronary microvascular dysfunction in symptomatic patients without significant epicardial stenosis. 无明显心外膜狭窄的有症状患者冠状动脉微血管功能障碍。

Cardiology journal Pub Date : 2025-07-04 DOI: 10.5603/cj.105362

Marcin Rogała, Michał Hawranek, Shraddha Singh, Wiktor Kuliczkowski, Krzysztof Malinowski, Łukasz Pyka, Jacek Arkowski, Andrzej Lekston, Mariusz Gąsior, Bartosz Hudzik

引用次数: 0

The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing primary percutaneous intervention and receiving abciximab. P2Y12受体抑制剂对急性冠状动脉综合征患者经皮介入治疗并接受阿昔单抗治疗的临床结局的影响

Cardiology journal Pub Date : 2025-06-24 DOI: 10.5603/cj.104531

Onur Altınkaya, Selim Aydemir, Murat Özmen, Sidar Şiyar Aydın, Emrah Aksakal, Mustafa Özkoç, Rauf Macit, İbrahim Saraç, Yavuzer Koza, Muhammet Hakan Taş

{"title":"The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing primary percutaneous intervention and receiving abciximab.","authors":"Onur Altınkaya, Selim Aydemir, Murat Özmen, Sidar Şiyar Aydın, Emrah Aksakal, Mustafa Özkoç, Rauf Macit, İbrahim Saraç, Yavuzer Koza, Muhammet Hakan Taş","doi":"10.5603/cj.104531","DOIUrl":"https://doi.org/10.5603/cj.104531","url":null,"abstract":"Background: Our study compared the effect of P2Y12 receptor inhibitors in combination with abciximab on clinical outcomes in patients with acute coronary syndrome (ACS).Methods: Our study is retrospective, consisting of 852 consecutive ACS patients who presented to our clinic between 2015 and 2021, underwent primary percutaneous coronary intervention (PCI), and received abciximab in addition to dual antiplatelet therapy. The P2Y12 receptor inhibitors were compared in terms of in-hospital and 1-year major adverse cardiac events (MACE), and clinically significant in-hospital and 1-year bleeding complications.Results: The patients' mean age was 60.4 ± 11 years, and 702 (82.4%) were male. In-hospital MACE, in-hospital mortality, 1-year MACE, and 1-year mortality were significantly higher in the clopidogrel group compared to the ticagrelor group. There was no significant difference in the development of in-hospital and 1-year bleeding between clopidogrel and the more potent P2Y12 receptor inhibitors. According to the BARC score, there was no difference in major bleeding between ticagrelor and clopidogrel (p = 0.641), but minor bleeding was significantly lower in the ticagrelor group (p < 0.001). In logistic regression analysis, the 1-year MACE rate was lower in the potent P2Y12 receptor inhibitors group compared to clopidogrel. At the same time, no association was found with short- and long-term mortality, bleeding, or in-hospital MACE.Conclusions: In our study, potent P2Y12 receptor inhibitors combined with abciximab decreased 1-year MACE without significantly increasing bleeding in ACS patients undergoing PCI compared to clopidogrel. This study suggests that potent P2Y12 receptor inhibitors can be safely used with abciximab, considering the bleeding risk.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144478236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intracoronary adrenaline for the treatment of refractory no-reflow phenomenon: A single-centre experience. 冠状动脉内肾上腺素治疗难治性无血流现象：单中心经验。

Cardiology journal Pub Date : 2025-06-12 DOI: 10.5603/cj.102975

Piotr Desperak, Marcin Osuch, Jarosław Madowicz, Justyna Małyszek-Tumidajewicz, Elżebieta Wojtynek, Michał Hawranek

引用次数: 0

The relationship between inspiratory muscle strength and exercise tolerance in patients with coronary heart disease. 冠心病患者吸气肌力量与运动耐量的关系。

Cardiology journal Pub Date : 2025-06-12 DOI: 10.5603/cj.102835

Tao Shen, Jinglin Li, Yanxin Song, Chuan Ren, Wei Zhao

{"title":"The relationship between inspiratory muscle strength and exercise tolerance in patients with coronary heart disease.","authors":"Tao Shen, Jinglin Li, Yanxin Song, Chuan Ren, Wei Zhao","doi":"10.5603/cj.102835","DOIUrl":"https://doi.org/10.5603/cj.102835","url":null,"abstract":"Background: There has been insufficient research on the assessment of exercise capacity in patients with coronary heart disease (CHD) following percutaneous coronary intervention (PCI) who exhibit inspiratory muscle weakness (IMW).Methods: A retrospective cohort study involving CHD patients who underwent PCI at Peking University Third Hospital Heart Rehabilitation Center between January 2019 and December 2021 was conducted. Patients who had undergone inspiratory muscle testing and cardiopulmonary exercise testing (CPET) were included, and their clinical data were collected and analyzed.Results: A total of 571 post-PCI CHD patients were included in the study. The average age was 60.8 ± 4.3 years, and 479 male patients (83.9%) were included. The average maximal inspiratory pressure (MIP) of the enrolled patients was 90.7 ± 26.1 cm H₂O, with 56 patients (9.8%) presenting with IMW. The IMW group had lower peak oxygen uptake (VO₂peak) (17.4 ± 4.2 vs. 19.3 ± 5.1 ml/min/kg, P < 0.001) and oxygen uptake efficiency slopes (OUES) (1464.7 ± 368.5 vs. 1619.2 ± 400.4, P=0.004). MIP correlated with VO₂peak (r = 0.719, P < 0.001) and OUES (r = 0.622, P < 0.001). Multivariate regression analysis revealed that VO₂peak (OR = 0.917, 95% CI = 0.858 ~ 0.980) and history of chronic obstructive pulmonary disease (COPD) (OR = 1.705, 95% CI = 0.934 ~ 3.112) were independent risk factors for IMW.Conclusions: After PCI, CHD patients exhibiting IMW, especially those with comorbid COPD, demonstrated reduced exercise tolerance and oxygen uptake efficiency.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient-tailored stent: are we there yet? 患者定制支架：我们做到了吗？

Cardiology journal Pub Date : 2025-06-12 DOI: 10.5603/cj.103757

Piotr Arski, Jakub M Zimodro, Magda Mucha, Paweł Jańczak, Arkadiusz Pietrasik, Aleksandra Gąsecka

{"title":"Patient-tailored stent: are we there yet?","authors":"Piotr Arski, Jakub M Zimodro, Magda Mucha, Paweł Jańczak, Arkadiusz Pietrasik, Aleksandra Gąsecka","doi":"10.5603/cj.103757","DOIUrl":"https://doi.org/10.5603/cj.103757","url":null,"abstract":"Percutaneous coronary intervention (PCI) has become a routine revascularization strategy. PCI outcome is affected by patient- and procedure-related factors. Stent design has evolved to overcome the risk of thrombosis and restenosis associated with stent implantation. Bare metal stents were followed by two generations of drug-eluting stents with different strut sizes, polymer types, and antiproliferative drug classes. Modern technologies comprising polymer-free stents, bioresorbable vascular scaffolds, and titanium-nitride-oxide-coated stents are intensively studied. The choice of the appropriate stent is crucial for PCI success, especially in high-risk settings. Hence, to establish a strategy for patient-tailored stent choice, we aimed to discuss the efficacy and safety of coronary stents in specific procedural and clinical scenarios. We concluded that the current evidence may encourage the use of (i) sirolimus-eluting stents (SES) in small vessel disease, (ii) biodegradable-polymer SES in multivessel PCI, (iii) everolimus-eluting stents (EES) and zotarolimus-eluting stents in bifurcation lesions, (iv) EES in chronic total occlusions, (v) SES, EES, and polymer-free stents in diabetic patients, (vi) ultrathin biodegradable-polymer DES and titanium-nitride-oxide-coated stents in acute coronary syndrome, and (vii) polymer-free biolimus-eluting stents in high bleeding-risk patients. Further randomized trials are required to established firm recommendations.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preclinical safety and performance evaluation of a highly-flexible peripheral polytetrafluoroethylene-covered stent. 高柔性聚四氟乙烯外周支架的临床前安全性和性能评价。

Cardiology journal Pub Date : 2025-05-30 DOI: 10.5603/cj.91079

Armando Tellez, Marta Mazur, Mateusz Kachel, Adam Janas, Carlos Fernandez, Karolina Łukasik, Sabrina N Evans, Juliana Castro, Eduardo Cordeiro, Luciano Curado, Piotr Buszman

{"title":"Preclinical safety and performance evaluation of a highly-flexible peripheral polytetrafluoroethylene-covered stent.","authors":"Armando Tellez, Marta Mazur, Mateusz Kachel, Adam Janas, Carlos Fernandez, Karolina Łukasik, Sabrina N Evans, Juliana Castro, Eduardo Cordeiro, Luciano Curado, Piotr Buszman","doi":"10.5603/cj.91079","DOIUrl":"https://doi.org/10.5603/cj.91079","url":null,"abstract":"Background: Sten graft implantation faces challenges such as deliverability issues, fracture risk, and subsequent restenosis. Recent advancements have introduced thinner coatings for increased flexibility and improved biocompatibility. The aim herein was to assess the safety and performance of a highly flexible cobalt-chromium stent covered with polytetrafluoroethylene (PTFE) in a preclinical model.Methods: In total 6 PTEF-covered stent grafts 6mm x 38mm cobalt-chromium, (Solaris BXTM, Scitech Produtos Medicos) were implanted compared to 5 controls ( BeGraftTM, Bentley InnoMed GmbH) in the iliac arteries of 11 swine. Stents were evaluated with angiography, high-definition IVUS, and histology for 28 days.Results: All animals underwent successful implantation with 100% survival at follow-up. At 28 days, there was no statistically significant difference in MLD compared to baseline in both groups (test, 5.2 ± 0.7 mm vs 5.3 ± 0.6 mm, p = 0.8; control, 4.9 ± 0.7 mm vs 5.1 ± 0.5 mm, p = 0.8), indicating no LLL (test, -0.2 ± 0.16 vs control, -0.18 ± 0.16 mm; p = 0.8). IVUS revealed a tendency for the less neointimal area in the test group (3.75 ± 0.9mm² vs 5.69 ± 2.2 mm²; p = 0.08), resulting in a tendency toward higher % AS in the control arm (14.07 ± 3.42% vs 20 ± 7%; p = 0.1). Microscopic evaluation revealed minimal vascular injury (test 0.1 ± 0.3 vs control 0.1 ± 0.1) and complete endothelialization coverage (test, 3.2 ± 0.8 vs control 3.8 ± 0.3) in both groups, with minimal inflammation(test vs. control: per strut 0.02 ± 0.06 vs. 0.14 ± 0.22; neointimal 1.2 ± 0.6 vs 1.1 ± 0.4; medial 0.3 ± 0.4 vs 0.3 ± 0.4).Conclusion: Solaris BXTM demonstrated highly flexible and biocompatible, with minimal vascular injury, and reduced neointimal hyperplasia compared to the control.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterization of Patients and Treatment Outcomes in Severe Tricuspid Regurgitation (CAPTURE) - study design. 严重三尖瓣反流（CAPTURE）患者特征和治疗结果——研究设计。

Cardiology journal Pub Date : 2025-05-22 DOI: 10.5603/cj.104429

Adam Rdzanek, Adam Piasecki, Mariusz Tomaniak, Ewa Pędzich, Agata Markiewicz, Michał Chmielecki, Jerzy Pręgowski, Sebastian Stefaniak, Witold Streb, Jarosław Trębacz, Krzysztof Reczuch, Piotr Suwalski, Marcin Fijałkowski, Andrzej Gackowski, Piotr Szymański, Agnieszka Kapłon-Cieślicka, Wojciech Wojakowski, Piotr Scisło, Marek Grygier

引用次数: 0

Successful experience of transcatheter residual right-to-left shunting closure after patent foramen ovale occlusion. 卵圆孔未闭后经导管残余右至左分流闭合的成功经验。

Cardiology journal Pub Date : 2025-05-20 DOI: 10.5603/cj.99783

Lu He, Xiao-Qin Liu, Xing-Ye Wang, Ya-Juan Du, Yu-Shun Zhang

{"title":"Successful experience of transcatheter residual right-to-left shunting closure after patent foramen ovale occlusion.","authors":"Lu He, Xiao-Qin Liu, Xing-Ye Wang, Ya-Juan Du, Yu-Shun Zhang","doi":"10.5603/cj.99783","DOIUrl":"https://doi.org/10.5603/cj.99783","url":null,"abstract":"Background: Residual shunt after patent foramen ovale (PFO) occlusion is associated with recurrent stroke, and limited literature address the specific management of such cases. Herein we report our experience with secondary interventional treatment.Methods: From July 2020 to January 2023, patients who underwent PFO occlusion for more than one year with residual right-to-left shunting (rRLS) screened by contrast transthoracic echocardiography (cTTE) constituted the study population. A retrospective analysis of the basic, procedural, and follow-up data was performed.Results: A total of 35 patients with large rRLS were admitted to our center. Fourteen patients underwent transcatheter rRLS closure. Transesophageal echocardiography (TEE) clearly showed the color blood flow profile, and cTEE showed a large rRLS in 12 cases. TEE showed a small outlet near the left exit of the rRLS, and cTEE showed a small rRLS in two cases. Type I rRLS accounted for 71.4%, residual PFO, and residual atrial septal defect (ASD) for 14.3%, respectively. Secondary transcatheter interventions were successful in 12 patients (85.7%). No complications were observed. Six cases of type I rRLS were closed with ASD occluders and two with an ADO-II device. Two residual PFO and two residual ASD were implanted with PFO occluders. cTTE was performed six months after the procedure, with complete closure in 12 patients.Conclusion: TEE not only helps to improve interventional strategies to reduce residual shunt in primary occlusion but also helps in the screening of patients who are truly suitable for secondary intervention. ASD occluders can be considered as an alternative device for type I rRLS.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting factor XI as a compromise between thrombosis and bleeding. 靶向因子XI作为血栓和出血之间的折衷。

Cardiology journal Pub Date : 2025-05-13 DOI: 10.5603/cj.102145

Aleksandra Żuk-Łapan, Olga Jakubik, Michał Pałuchowski, Magdalena Gajewska, Sylwester Rogula, Michał Łomiak, Aleksandra Gąsecka

{"title":"Targeting factor XI as a compromise between thrombosis and bleeding.","authors":"Aleksandra Żuk-Łapan, Olga Jakubik, Michał Pałuchowski, Magdalena Gajewska, Sylwester Rogula, Michał Łomiak, Aleksandra Gąsecka","doi":"10.5603/cj.102145","DOIUrl":"https://doi.org/10.5603/cj.102145","url":null,"abstract":"Thromboembolic diseases have long been a leading cause of morbidity and mortality, necessitating advances in anticoagulant drugs. Heparins, vitamin K inhibitors, and direct oral anticoagulants (DOACs) are well-established drug classes that help prevent thromboembolic complications. While effective, they pose significant risks during long-term therapy, including bleeding, osteoporosis, heparin-induced thrombocytopenia, and the need for frequent monitoring and dose adjustments. Factor XI (FXI) inhibitors represent an innovative approach in anticoagulation therapy, aiming to balance thromboembolic events with the risk of bleeding complications. They include: a) orally administered small molecule inhibitors such as milvexian and asundexian; b) monoclonal antibodies such as abelacimab, osocimab, and xisomab, which specifically bind and inactivate FXI; c) FXI-antisense oligonucleotide (FXI-ASO), which downregulate FXI synthesis at the mRNA level and reduce plasma FXI concentrations. Available data indicate that FXI inhibitors decrease the risk of thromboembolic events and are associated with a lower incidence of major bleeding than current gold standard methods. Hence, FXI inhibitors may become the preferred anticoagulant class, especially for patients with elevated bleeding risk. Their development is an important step in the history of anticoagulant therapy, striving to find a balance between preventing thromboembolism and reducing bleeding risk, ultimately improving patient outcomes. In this context, a discussion on the characteristics of FXI inhibitors, a summary on data regarding the efficacy and safety of FXI inhibitors based on preclinical and clinical studies, and an outline of future perspectives regarding therapeutic strategies of FXI inhibition in venous thrombosis are presented in this study.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0